Early Evaluation of Neoadjuvant Immunotherapy Response Using 68Ga-grazytracer PETCT in Resectable Non-Small Cell Lung Cancer Patients Aged 18 to 75 Years

What this Trial Is About

Researchers are evaluating the use of 68Ga-grazytracer PETCT imaging to assess early responses to neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer NSCLC stages IB to IIIA. The study aims to improve noninvasive methods for determining how cancer responds to immunotherapy before surgery. This observational study involves patients who have been clinically staged and meet specific eligibility criteria, including age and health status. Participants receive standardized neoadjuvant immunotherapy every three weeks for three cycles. Patients with nonsquamous NSCLC are treated with pembrolizumab combined with platinum-pemetrexed, while those with squamous NSCLC receive pembrolizumab plus platinum-paclitaxel. 68Ga-grazytracer PETCT scans are performed twice once before treatment begins and again before the third cycle to monitor immune response. During the study, patients will undergo imaging assessments along with pathological evaluations after surgery to determine major pathological response within three weeks post-operation. Researchers focus on comparing imaging responses and PETCT results to the pathological findings. The study also monitors participants performance status and survival expectations, with informed consent obtained before enrollment. The total study duration extends through treatment, surgery, and follow-up assessments to evaluate treatment effects comprehensively.

68Ga-grazytracer PET/CT for Early Assessment of Response to Neoadjuvant Immunotherapy in Resectable NSCLC